Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial
Topline readout of data from NORSE TWO targeted for calendar Q3 2021New Biologics License Application (BLA) filing anticipated in calendar...
News
Metta World Peace, Former NBA Allstar, Entrepreneur and Mental Health Advocate, Named Chief Impact Director at OOTify, a New Model for Mental Healthcare
Los Angeles , June 08, 2021 (GLOBE NEWSWIRE) -- OOTify, a new mental health hub powered by artificial intelligence (AI),...
Scipher Medicine and Leading Medical Researchers in Network and Data Science Compress Time to Identify COVID-19 Treatments From Years to Months
Study demonstrates Scipher Medicine’s ability to analyze patient data to identify novel treatments.Scipher will focus on pharma collaborations in autoimmune...
IntelGenx’s VetaFilm™ Platform to be Evaluated by One of the World’s Fastest Growing Animal Healthcare Companies
SAINT LAURENT, Quebec, June 08, 2021 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today...
Strong Predictive Value of Organoid-Based PARIS® Test to Identify Personalized Treatments in Advanced Cancers Presented at 2021 ASCO Annual Meeting
SEATTLE, June 08, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on patient-derived tumor...
iCAD Signs Global Distribution Agreement with Sectra
Agreement will expand access to ProFound AI and ProFound AI Risk to more facilities and imaging centers worldwideNASHUA, N.H., June...
Celsion Corporation Appoints Dr. Stacy R. Lindborg to its Board of Directors
25-year pharmaceutical industry executive brings broad drug development perspective Replaces Alberto Martinez, MD LAWRENCEVILLE, N.J., June 08, 2021 (GLOBE NEWSWIRE)...
Saniona to Present Preclinical Data on SAN711 at the 7th Congress of the European Academy of Neurology
PRESS RELEASE June 8, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it...
Pyxis Oncology Strengthens Leadership Team with Executive and Scientific Advisory Board Appointments
– Steve Monks, Ph.D., appointed as Chief Technical Officer, brings 20+ years in drug development and CMC, Quality, and Regulatory...
Immutep Reveals a New Anti-LAG-3 Research Program
SYDNEY, AUSTRALIA, June 08, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), the leading...
BrainsWay to Present at the Raymond James Human Health Innovation Conference
CRESSKILL, N.J. and JERUSALEM, June 08, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Ocuphire Announces Appointment of Jay S. Pepose, M.D., Ph.D. to Its Board of Directors
Dr. Pepose is Recognized as an Esteemed Key Opinion Leader in Ophthalmology with Nearly 40 Years of Experience as a...
CORRECTING AND REPLACING — PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting
Tumor reduction was observed in 83% (5 of 6) of HPV16-positive relapsed or refractory checkpoint inhibitor naïve advanced cancer patients...
InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab
Proof-of-concept trial will evaluate vilobelimab alone and in combination with pembrolizumabJENA, Germany, June 08, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V....
Mydecine Discovers Over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms
DENVER, June 08, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’),...
The Psyence Group Announces its Formal Entry into Jamaica with the Incorporation of its Wholly Owned Subsidiary, Psyence Jamaica Limited
TORONTO, June 08, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (“Psyence” or the “Company”) (PSYG:CSE), a Canadian public biotechnology company...
Humacyte Presents In Vivo Data on Biovascular Pancreas Transplantation for Type 1 Diabetes Treatment
Laboratory and preclinical models demonstrate biovascular pancreas platform technology may provide method to transplant islet cells that produce insulin in...
Kiniksa Outlines Next Steps for the Development of Mavrilimumab
- Defined regulatory pathway for Phase 3 clinical development of mavrilimumab in multiple indications - - Continued development in COVID-19-related...
Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D’Amour as Chief Scientific Officer
BROOKLYN, N.Y., June 08, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on...
ProMIS Neurosciences congratulates Biogen on FDA accelerated approval of aducanumab for Alzheimer’s disease
Approval of aducanumab offers real hope for patients and fuels development of next-generation therapies with more selective binding for toxic...